Cover Image

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak

Variable outcomes have been reported with cefiderocol in infections due to carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB). Nonetheless, it may be the only option for metallo-beta-lactamase-producing strains. We describe an outbreak of NDM-CRAB infections treated with cefidero...

Full description

Saved in:

Bibliographic Details
Main Authors:	Giovanna Travi (Author), Francesco Peracchi (Author), Marco Merli (Author), Noemi Lo Re (Author), Elisa Matarazzo (Author), Livia Tartaglione (Author), Alessandra Bielli (Author), Giorgia Casalicchio (Author), Fulvio Crippa (Author), Chiara S. Vismara (Author), Massimo Puoti (Author)
Format:	Book
Published:	MDPI AG, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Current State of Antimicrobial Treatment of Lower Respiratory Tract Infections Due to Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Marco Merli, et al.
Published: (2023)

Meropenem-Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature
by: Leonardo Francesco Rezzonico, et al.
Published: (2024)

Transmission cluster of cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii in cefiderocol-naïve individuals
by: Claudia Alteri, et al.
Published: (2024)

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant <i>Acinetobacter baumannii</i>
by: Arta Karruli, et al.
Published: (2023)

Challenges Facing Two Outbreaks of Carbapenem-Resistant <i>Acinetobacter baumannii</i>: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants
by: Montserrat Rodríguez-Aguirregabiria, et al.
Published: (2024)

Patient and facility characteristics of an NDM-producing Acinetobacter baumannii outbreak in California, 2020-2022
by: Lian Hsiao, et al.
Published: (2023)

Clinical and molecular features of NDM-producing Acinetobacter baumannii in a multicenter study in Israel
by: Amos Adler, et al.
Published: (2023)

Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study
by: Federica Calò, et al.
Published: (2023)

In Vitro Activity of Cefiderocol against a Global Collection of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Isolates
by: Harald Seifert, et al.
Published: (2023)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of <i>Acinetobacter baumannii</i> Clinical Isolates
by: Clara Ballesté-Delpierre, et al.
Published: (2022)

Monitoring Immune Dysfunction in Critically Ill Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Sepsis Treated with Regimens Including Cefiderocol: A Pilot Study to Identify Accessible Biomarkers to Stratify Patients' Prognosis
by: Antonella Frattari, et al.
Published: (2024)

Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in <i>Acinetobacter baumannii</i>
by: Natalia Kolesnik-Goldmann, et al.
Published: (2023)

In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against <i>Acinetobacter baumannii</i> Strains Recovered from Clinical Samples
by: Davide Carcione, et al.
Published: (2021)

In Vitro Activity of Cefiderocol on Multiresistant Bacterial Strains and Genomic Analysis of Two Cefiderocol Resistant Strains
by: Michela Padovani, et al.
Published: (2023)

Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management
by: Gabriele Cavazza, et al.
Published: (2024)

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?
by: Silvia Corcione, et al.
Published: (2022)

Metallo-Beta-Lactamases: NDM
by: Kamil Leis, et al.
Published: (2019)

Metallo-Beta-Lactamases: NDM
by: Kamil Leis, et al.
Published: (2019)

Disc Diffusion and ComASP<sup>®</sup> Cefiderocol Microdilution Panel to Overcome the Challenge of Cefiderocol Susceptibility Testing in Clinical Laboratory Routine
by: Gabriele Bianco, et al.
Published: (2023)

The solution to drug resistance of Gram-negative bacteria - Cefiderocol
by: Magdalena Kołodziej, et al.
Published: (2023)

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms
by: Monirul I. Sajib, et al.
Published: (2023)

Chelation in Antibacterial Drugs: From Nitroxoline to Cefiderocol and Beyond
by: Davorka Repac Antić, et al.
Published: (2022)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022)

Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series
by: Simone Mornese Pinna, et al.
Published: (2022)

Cefiderocol for Severe Carbapenem-Resistant <i>A. baumannii</i> Pneumonia: Towards the Comprehension of Its Place in Therapy
by: Emanuele Rando, et al.
Published: (2021)

Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
by: Stamatis Karakonstantis, et al.
Published: (2022)

Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria
by: Cristina Kirkegaard-Biosca, et al.
Published: (2024)

Occurrence and Characterization of NDM-1-Producing <i>Shewanella</i> spp. and <i>Acinetobacter portensis</i> Co-Harboring <i>tet</i>(X3) in a Chinese Dairy Farm
by: Ruichao Li, et al.
Published: (2022)

Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study
by: Gabriele Palermo, et al.
Published: (2023)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Cefiderocol
by: Julia Zimmer, et al.
Published: (2021)

Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations
by: Andrea Marino, et al.
Published: (2022)

Cefiderocol susceptibility of Achromobacter spp.: study of an accurately identified collection of 230 strains
by: Vincent Jean-Pierre, et al.
Published: (2024)

The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
by: Yasaman Taheri, et al.
Published: (2021)

Optimized fosfomycin regimens for treating carbapenem‐resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function
by: Nattapong Tidwong, et al.
Published: (2024)

First detection of a plasmid-encoded New-Delhi metallo-beta-lactamase-1 (NDM-1) producing Acinetobacter baumannii using whole genome sequencing, isolated in a clinical setting in Benin
by: Carine Yehouenou, et al.
Published: (2021)

Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates
by: Bing Zhao, et al.
Published: (2021)

Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including <i>Acinetobacter baumannii</i>
by: Tetsushu Onita, et al.
Published: (2023)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
by: Karol Lorenc Lorenc, et al.
Published: (2019)

Real-world clinical outcomes of cefiderocol therapy in the Veterans Health Administration, 2019-2022
by: Eva Amenta, et al.
Published: (2023)

Cefiderocol - a promising new antibiotic for the antibiotic-resistant pathogens of the highest epidemiological priority
by: Karol Lorenc Lorenc, et al.
Published: (2019)